← Eichor
Study identifier: NCT06934200 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels

Condition: Food Hypersensitivity  ·  Sponsor: Johns Hopkins University

PhasePhase 2
Planned participants32
Who can joinAll sexes, 1 Year to 55 Years
Healthy volunteersNo

About this study

In this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen enabling a person to increase tolerance to the food(s) that the person is allergic to. The investigators would also like to learn if participants who demonstrate increased tolerance to food after 24 weeks of omalizumab, can introduce the food into the diet utilizing an additional 8 weeks (about 2 months) of twice weekly omalizumab injections.

This description comes directly from the study's public registry record.

Talk to the study team

Robert Wood, MD  ·  410-955-5883  ·  rwood@jhmi.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Johns HopkinsBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06934200